Dendreon, the manufacture of the only FDA approved immunologic therapy for prostate cancer had been burdened with significant debt. The debt came from their R&D of Provenge, their seeking FDA approval and the construction of three manufacturing plants to produce the treatment. Sadly, the company was unable to get its income ahead of its debt [...]
It was announced this morning that Dendreon (the manufactures of Provenge) has filed for voluntary Chapter 11 Bankruptcy. After having spoken with a representative at Dendreon I have learned that the company has been in negotiations with its creditors and agreed to voluntarily file for financial reorganization. The agreement that Dendreon has reached with their [...]
A recent announcement stated that Dendreon’s immunotherapy Provenge (sipuleucel-T) is too expensive to be used as a treatment for advanced prostate cancer under the National Health Service in England. In preliminary draft guidelines out this morning, the National Institute for Health and Care Excellence has rejected the drug’s use to treat men with metastatic prostate [...]
My blog post last Friday was among the top twenty most important ones I have written. I want to be sure that if you have taken Provenge commercially, meaning not during a clinical trial, you need to know that you might have been under-dosed and might need to be retreated. Dendreon, the company that manufactures [...]
Sequencing of the various new advanced prostate cancer treatments remains a hot topic in our community. What treatment should come first and will the combination of various treatments be even more effective? These types of questions are constantly buzzing around us and they will continue to as long as we develop new treatments. The only [...]
The recent AUA meetings in Atlanta had a number of interesting abstracts presented that concern men with advanced prostate cancer. Some of the more interesting abstracts were look back analysis of sipuleucel-T (Provenge) done by consultants for Dendreon, the company who manufactures Provenge. They took the data from the al three of the phase III [...]
According to an article written by Reuters some doctors have raised doubts about the efficacy of Provenge, known scientifically as sipuleucel-T. Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy and the story seems to continue even to today. The current issue has been raised by Marie Huber, a trained scientist [...]
The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California. Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference. [...]
Yesterday Dendreon, the producers of Provenge, received word from the FDA that their plant in California had been approved to manufacture Provenge. This afternoon they received a positive response from the Centers for Medicare and Medicaid Services (CMS) that a final National Coverage Decision (NCD) for Provenge has been issued requiring Medicare contractors to cover [...]
Early this evening Dendreon received the nod from the FDA to use their new manufacturing plant in Seal Beach, California. The approval of this plant will allow the company to now service the men with advanced prostate cancer in Hawaii as well as more efficiently service those in Western United States with Provenge. When coupling [...]
